Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20729579 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL200722 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL26893965 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL91558 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL27043970 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL692637 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL200978 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL72827 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL13216436 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL2965236 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4628167-A2 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | Alkermes, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4065585-B1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES INC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | PFIZER INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250092063-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-03-20 | — | — | US | disclosed |
| US-20250034173-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240368182-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-11-07 | — | — | US | disclosed |
| WO-2022140316-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220194958-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-06-23 | — | — | US | disclosed |
| US-20220194958-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-06-23 | — | — | US | disclosed |
| US-20220144771-A1 | PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3923933-A1 | PYRROLIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210155636-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-27 | — | — | US | disclosed |
| WO-2020167701-A1 | PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-0646596-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1999-05-26 | — | — | EP | disclosed |
| US-5849893-A | Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| EP-0646596-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092063-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | HCRTR2, HCRTR1, CNR2 | CHRM2 127/4885CHRM1 367/4885CHRM3 23/4885 |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | KRAS, NRAS, TP53 | CHRM2 4872/4885CHRM1 4878/4885CHRM3 4875/4885 |
| US-20210155636-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | HCRTR2, HCRTR1, CNR2 | CHRM2 127/4885CHRM1 367/4885CHRM3 23/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | CHRM2 2762/4885CHRM1 2001/4885CHRM3 2036/4885 |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | DPYD, PNPO, TYMP | CHRM2 3052/4885CHRM1 2731/4885CHRM3 2615/4885 |
| US-20240368182-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | HCRTR2, HCRTR1, CNR2 | CHRM2 127/4885CHRM1 367/4885CHRM3 23/4885 |
| US-20250034173-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | DPYD, PNPO, TYMP | CHRM2 3052/4885CHRM1 2731/4885CHRM3 2615/4885 |
| US-20220144771-A1 | PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | CHRM2 721/4885CHRM1 509/4885CHRM3 550/4885 |
| US-20220194958-A1 | Substituted Macrocyclic Compounds and Related Methods of Treatment | HCRTR2, HCRTR1, CNR2 | CHRM2 127/4885CHRM1 367/4885CHRM3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.